Abstract
The most common of the primary immunodeficiency diseases are those that involve inadequate antibody production. The characteristic presentation of these disorders is recurrent sinopulmonary infections. An arrest in B cell development at the pre-B cell stage leads to agammaglobulinemia and an insignificant number of B cells. X-linked agammaglobulinemia is the most common of these developmental arrests while the autosomal recessive agammaglobulinemias comprise a small minority of the total cases. Likewise, the most common form of the hyper-IgM syndromes (CD40 ligand deficiency) is X-linked. Of the autosomal recessive forms, CD40 deficiency is basically identical to the X-linked form in its clinical phenotype where, in addition to inadequate antibody production, there is defective T cell signaling through the CD40-CD40L interaction. Aside from CD40 deficiency, the other recessive forms of hyper-IgM syndrome have adequate T cell function. IgA deficiency is the most common and the most benign of the B cell disorders. Common variable immunodeficiency is diverse in its presentation and clinical course. The pathophysiology of this disease is multifactorial and frequently ill defined, often making it a diagnosis of exclusion. A working knowledge of identifiable PIDDs is essential in both recognizing when to suspect immunodeficiency and making a diagnosis.
Keywords: B lymphocyte, antibody, deficiencies, clinical evaluation.
Cardiovascular & Hematological Disorders-Drug Targets
Title:Evaluation of B Lymphocyte Deficiencies
Volume: 13 Issue: 2
Author(s): John D. Vickery, Christie F. Michael and D. Betty Lew
Affiliation:
Keywords: B lymphocyte, antibody, deficiencies, clinical evaluation.
Abstract: The most common of the primary immunodeficiency diseases are those that involve inadequate antibody production. The characteristic presentation of these disorders is recurrent sinopulmonary infections. An arrest in B cell development at the pre-B cell stage leads to agammaglobulinemia and an insignificant number of B cells. X-linked agammaglobulinemia is the most common of these developmental arrests while the autosomal recessive agammaglobulinemias comprise a small minority of the total cases. Likewise, the most common form of the hyper-IgM syndromes (CD40 ligand deficiency) is X-linked. Of the autosomal recessive forms, CD40 deficiency is basically identical to the X-linked form in its clinical phenotype where, in addition to inadequate antibody production, there is defective T cell signaling through the CD40-CD40L interaction. Aside from CD40 deficiency, the other recessive forms of hyper-IgM syndrome have adequate T cell function. IgA deficiency is the most common and the most benign of the B cell disorders. Common variable immunodeficiency is diverse in its presentation and clinical course. The pathophysiology of this disease is multifactorial and frequently ill defined, often making it a diagnosis of exclusion. A working knowledge of identifiable PIDDs is essential in both recognizing when to suspect immunodeficiency and making a diagnosis.
Export Options
About this article
Cite this article as:
Vickery D. John, Michael F. Christie and Lew Betty D., Evaluation of B Lymphocyte Deficiencies, Cardiovascular & Hematological Disorders-Drug Targets 2013; 13(2) . https://dx.doi.org/10.2174/1871529X11313020006
DOI https://dx.doi.org/10.2174/1871529X11313020006 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Last Findings on Dual Inhibitors of Abl and Src Tyrosine-Kinases
Mini-Reviews in Medicinal Chemistry Ex Vivo Liver – Directed Gene Therapy for the Treatment of Metabolic Diseases: Advances in Hepatocyte Transplantation and Retroviral Vectors
Current Gene Therapy The Endocannabinoid System and Multiple Sclerosis
Current Pharmaceutical Design Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem
Current Drug Targets Aging and Inflammation: Etiological Culprits of Cancer
Current Aging Science Immunogenicity and Tolerability of Yellow Fever Vaccination in 23 French HIV-Infected Patients
Current HIV Research The Peripheral Benzodiazepine Receptor: A Promising Therapeutic Drug Target
Current Medicinal Chemistry Latest Updates in Dengue Fever Therapeutics: Natural, Marine and Synthetic Drugs
Current Medicinal Chemistry A Brief Overview of Tyrosine Hydroxylase and α-Synuclein in the Parkinsonian Brain
CNS & Neurological Disorders - Drug Targets The Blood-brain Barrier and the Outer Blood-retina Barrier
Medicinal Chemistry Reviews - Online (Discontinued) The Molecular Genetics of Lentiviral Vectors - Current and Future Perspectives
Current Gene Therapy Therapeutic Potential of Erythropoietin in Retinal and Optic Nerve Diseases
CNS & Neurological Disorders - Drug Targets Gene Transfer to the Central Nervous System: Current State of the Art of the Viral Vectors
Current Genomics GEMSP: A New Therapeutic Approach to Multiple Sclerosis
Central Nervous System Agents in Medicinal Chemistry The Immune System of Cancer Patients
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Contribution of γδ T Cells to the Pathogenesis of EAE and MS
Current Molecular Medicine HPV Cervical Infection and Immunodysregulation: Synergistic Risks for Neoplasia-Review
Current Women`s Health Reviews An Overview of Acute Flaccid Myelitis
CNS & Neurological Disorders - Drug Targets Dehydroepiandrosterone (DHEA): A Steroid with Multiple Effects. Is there Any Possible Option in the Treatment of Critical illness?
Current Medicinal Chemistry